Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study

Stefan Esser; A. Haberl; F. Mulcahy; J. Gölz; A. Lazzarin; E. Teofilo; J. Vera; A. Körber; S. Staszewski

Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study

Stefan Esser, A. Haberl, F. Mulcahy, J. Gölz, A. Lazzarin, E. Teofilo, J. Vera, A. Körber, S. Staszewski

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF) 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU). Methods: European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-naïve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results: Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing=failure) at week 48, 34% of patients (23/67; 95% CI: 23%-47%) had plasma HIV-1 RNA

Original language	English
Pages (from-to)	427-436
Number of pages	10
Journal	European Journal of Medical Research
Volume	16
Issue number	10
Publication status	Published - Oct 10 2011

Keywords

HIV-1
Injecting drug users
Methadone
Tenofovir DF

ASJC Scopus subject areas

Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study'. Together they form a unique fingerprint.

Cite this

Esser, S., Haberl, A., Mulcahy, F., Gölz, J., Lazzarin, A., Teofilo, E., Vera, J., Körber, A., & Staszewski, S. (2011). Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study. European Journal of Medical Research, 16(10), 427-436.

Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment : Results of a 48-week open-label study. / Esser, Stefan; Haberl, A.; Mulcahy, F.; Gölz, J.; Lazzarin, A.; Teofilo, E.; Vera, J.; Körber, A.; Staszewski, S.

In: European Journal of Medical Research, Vol. 16, No. 10, 10.10.2011, p. 427-436.

Research output: Contribution to journal › Article › peer-review

Esser, S, Haberl, A, Mulcahy, F, Gölz, J, Lazzarin, A, Teofilo, E, Vera, J, Körber, A & Staszewski, S 2011, 'Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study', European Journal of Medical Research, vol. 16, no. 10, pp. 427-436.

Esser, Stefan ; Haberl, A. ; Mulcahy, F. ; Gölz, J. ; Lazzarin, A. ; Teofilo, E. ; Vera, J. ; Körber, A. ; Staszewski, S. / Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment : Results of a 48-week open-label study. In: European Journal of Medical Research. 2011 ; Vol. 16, No. 10. pp. 427-436.

@article{8574656305fb49e38971fb58a6317d08,

title = "Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: Results of a 48-week open-label study",

abstract = "Objective: To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF) 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU). Methods: European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-na{\"i}ve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results: Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing=failure) at week 48, 34% of patients (23/67; 95% CI: 23%-47%) had plasma HIV-1 RNA ",

keywords = "HIV-1, Injecting drug users, Methadone, Tenofovir DF",

author = "Stefan Esser and A. Haberl and F. Mulcahy and J. G{\"o}lz and A. Lazzarin and E. Teofilo and J. Vera and A. K{\"o}rber and S. Staszewski",

year = "2011",

month = oct,

day = "10",

language = "English",

volume = "16",

pages = "427--436",

journal = "European Journal of Medical Research",

issn = "0949-2321",

publisher = "BioMed Central",

number = "10",

}

TY - JOUR

T1 - Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment

T2 - Results of a 48-week open-label study

AU - Esser, Stefan

AU - Haberl, A.

AU - Mulcahy, F.

AU - Gölz, J.

AU - Lazzarin, A.

AU - Teofilo, E.

AU - Vera, J.

AU - Körber, A.

AU - Staszewski, S.

PY - 2011/10/10

Y1 - 2011/10/10

N2 - Objective: To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF) 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU). Methods: European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-naïve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results: Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing=failure) at week 48, 34% of patients (23/67; 95% CI: 23%-47%) had plasma HIV-1 RNA

AB - Objective: To assess efficacy, adherence and tolerability of once daily antiretroviral therapy containing tenofovir disoproxil fumarate (DF) 300 mg in HIV-1-infected former injecting drug users receiving opiate treatment (IVDU). Methods: European, 48-week, open-label, single-arm, multicenter study. Patients were either antiretroviral therapy-naïve, restarting therapy after treatment discontinuation without prior virological failure or switching from existing stable treatment. Results: Sixty-seven patients were enrolled in the study and 41 patients completed treatment. In the primary analysis (intent-to-treat missing=failure) at week 48, 34% of patients (23/67; 95% CI: 23%-47%) had plasma HIV-1 RNA

KW - HIV-1

KW - Injecting drug users

KW - Methadone

KW - Tenofovir DF

UR - http://www.scopus.com/inward/record.url?scp=80055030076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055030076&partnerID=8YFLogxK

M3 - Article

C2 - 22024421

AN - SCOPUS:80055030076

VL - 16

SP - 427

EP - 436

JO - European Journal of Medical Research

JF - European Journal of Medical Research

SN - 0949-2321

IS - 10

ER -